---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-057889"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2023-12-15T23:59:59+00:00"
generated_at: "2026-06-07T11:41:05.216664+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics appoints Dr. Han Ying as CEO effective Jan 15, 2024; Dr. Charles Wu retires for health reasons

## Summary
- CEO Dr. Charles Wu resigns as CEO and board member effective Jan 15, 2024 due to retirement for health reasons; no disagreements.
- Dr. Han Ying appointed CEO effective Jan 15, 2024; currently a director; base salary $350,000.
- Dr. Ying has over 20 years experience in immunology, biotech startups, and cancer immunotherapy; previously COO of Base Therapeutics.
- CEO severance provides 12 months base salary upon involuntary termination.

## SEC filing metadata
- accession: 0001140361-23-057889
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2023-12-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036123057889/0001140361-23-057889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036123057889/ef20016739_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-057889
- JSON: https://secwatch.observer/filing/0001140361-23-057889.json
- Plain text: https://secwatch.observer/filing/0001140361-23-057889.txt

## Key facts
- Executive change
  Han Ying was appointed as Chief Executive Officer at GYRE THERAPEUTICS, INC..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On December 13, 2023, Gyre Therapeutics, Inc. (the “Company”) appointed Dr. Han Ying as the Company’s Chief Executive Officer, effective January 15, 2024, to succeed Dr. Charles Wu, whose employment with the Company will terminate on such date pursuant to his retirement for health reasons.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036123057889/0001140361-23-057889-index.htm
- Executive change
  Charles Wu retired as Chief Executive Officer at GYRE THERAPEUTICS, INC..
  - Action: retired
  - Role: Chief Executive Officer
  source text: Dr. Charles Wu, whose employment with the Company will terminate on such date pursuant to his retirement for health reasons.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036123057889/0001140361-23-057889-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.